|Bid||478.28 x 100|
|Ask||478.64 x 100|
|Day's Range||472.32 - 480.86|
|52 Week Range||325.35 - 543.55|
|PE Ratio (TTM)||57.96|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Regeneron Pharmaceuticals has a slew of clinical trials going on, and studies evaluating REGN-2810 could be the most important.
Regeneron Pharmaceuticals has launched three new drugs that could kick-start sales growth over the coming years.
Despite competition, there are big demographic tailwinds supporting Eylea’s sale.